A Novel Ureteric Stent in Kidney Stone Patients and Oncology Patients Compared to a Conventional JJ Stent

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-99
SponsorUniversity of Southampton

About this trial

Urological stents and catheters often lead to inflammation, causing pain and infection in the urinary tract. Moreover, 80% of stents are associated with pain, negatively impacting on QoL and mental health. Offering novel designs with significantly lower E\&B leads to a reduction in UTIs and improves QoL. Reducing hospital admissions (from 3 to 1 per patient, annually) would free \>100,000 bed-nights, allowing the elderly to regain independence. Our proposed research could have a significant impact towards fulfilling the 'healthy-ageing' Grand Challenge. Additionally, the novel stent reduces prevalence of infections and therefore, of antibiotic prescriptions contributing to the Global AMR challenge.

Eligibility criteria

Qualifiers

Aged 18 years or over

Ureteric stents clinically indicated either due to kidney stones or abdominal/pelvic cancers compressing ureters

Previous experience with ureteric stents

Awaiting insersion/replacement of stents

Disqualifiers

Expected survival <4months

Unfit for stent insertion

Unable to comply with study processes Pregnancy

Trial design

Treatments tested in this trial

  • Experimental ureteric stent with specially shaped side-holes that prevent stagnation points (i.e., areas of low flow that cause particles to settle and E&B)
  • Qualitative interview

Treatment groups

50 Participants
are divided into 2 treatment groups

Sponsors and collaborators

University of Southampton

Lead sponsor

University Hospital Southampton NHS Foundation Trust

Collaborator

National Institute for Health Research, United Kingdom

Collaborator

University College London Hospitals

Collaborator